Chemical Component Summary

Name Gefitinib
Identifiers 3-chloro-4-fluoro-N-[(4Z)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4(1H)-ylidene]aniline
Formula C22 H24 Cl F N4 O3
Molecular Weight 446.90 g/mol
Type non-polymer
Isomeric SMILES COc1cc2[nH]cn\c(=N/c3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1
InChI InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)

Chemical Details

Formal Charge 0
Atom Count 55
Chiral Atom Count 0
Chiral Atoms
Bond Count 58
Aromatic Bond Count 17

Drug Info: DrugBank

DrugBank ID DB00317   (Stereoisomeric match)
Name Gefitinib
  • approved
  • investigational
Description Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. [Wikipedia]
  • 4-(3'-chloro-4'-Fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
  • Gefitinib
  • Iressa
  • N-(3-chloro-4-Fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
  • ZD 1839
Brand Names Iressa
Affected Organism Humans and other mammals
Indication For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
Pharmacology Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR is expressed on the cell surface of many normal cells and cancer cells.
Mechanism of action Gefitinib inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase by binding to the adenosine triphosphate (ATP)-binding site of the enzyme. Thus the function of the EGFR tyrosine kinase in activating the Ras signal transduction cascade is inhibited; and malignant cells are inhibited. Gefitinib is the first selective inhibitor of the EGFR tyrosine kinase which is also referred to as Her1 or ErbB-1. EGFR is overexpressed in the cells of certain types of human carcinomas - for example in lung and breast cancers. Overexpression leads to inappropriate activation of the apoptotic Ras signal transduction cascade, eventually leading to uncontrolled cell proliferation.
Route of administration Oral
  • Antineoplastic Agents
  • Antineoplastic and Immunomodulating Agents
  • BCRP/ABCG2 Inhibitors
  • BCRP/ABCG2 Substrates
  • Chemical Actions and Uses
ATC-Code L01XE02
AHFS-Code 10:00.00
CAS number 184475-35-2

Drug Targets

Name Sequence Search Pharmacological Action Actions
Epidermal growth factor receptor Search yes antagonist
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID: 21059682